BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Custirsen sodium: Additional Phase I/II data

In an open-label, international Phase I/II trial in 81 patients with advanced NSCLC, the 2-year survival rate was 30% in patients who received OGX-011 plus first-line chemotherapy, which included a platinum-based regimen plus gemcitabine. Additionally, the rates of complete response, partial response, stable disease and progression were 1%, 30%,...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >